Medivie Therapeutic (Israel) Top Management
MDVI Stock | ILA 32.50 0.50 1.56% |
Medivie Therapeutic employs about 11 people. The company is managed by 10 executives with a total tenure of roughly 66 years, averaging almost 6.0 years of service per executive, having 1.1 employees per reported executive. Analysis of Medivie Therapeutic's management performance can provide insight into the company performance.
Itai Hecht CEO Chief Executive Officer of the Company’s Subsidiary |
Menachem Cohen CEO Chief Executive Officer, Director |
Medivie |
Medivie Therapeutic Management Team Effectiveness
The company has return on total asset (ROA) of (1.0886) % which means that it has lost $1.0886 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5598) %, meaning that it generated substantial loss on money invested by shareholders. Medivie Therapeutic's management efficiency ratios could be used to measure how well Medivie Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.Medivie Therapeutic Workforce Comparison
Medivie Therapeutic is considered to be number one stock in number of employees category among its peers. The total workforce of Medical Instruments & Supplies industry is now estimated at about 25,525. Medivie Therapeutic adds roughly 11.0 in number of employees claiming only tiny portion of all equities under Medical Instruments & Supplies industry.
Medivie Therapeutic Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Medivie Therapeutic Price Series Summation is a cross summation of Medivie Therapeutic price series and its benchmark/peer.
Medivie Therapeutic Notable Stakeholders
A Medivie Therapeutic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medivie Therapeutic often face trade-offs trying to please all of them. Medivie Therapeutic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medivie Therapeutic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Itai Hecht | Chief Executive Officer of the Company’s Subsidiary | Profile | |
Menachem Cohen | Chief Executive Officer, Director | Profile | |
Uri BenOr | Vice President - Finance | Profile | |
Irit BenAmi | External Director | Profile | |
Yigal Fatran | External Director | Profile | |
Eyal Paauw | Independent Director | Profile | |
Omri Wolf | Internal Auditor | Profile | |
Uri Or | Chief Officer | Profile | |
Pr MBBS | Chief Scientist | Profile | |
Yigal Hevroni | Chairman of the Board | Profile |
About Medivie Therapeutic Management Performance
The success or failure of an entity such as Medivie Therapeutic often depends on how effective the management is. Medivie Therapeutic management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medivie management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medivie management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Medivie Therapeutic Limited develops and markets dental devices. Medivie Therapeutic Limited was founded in 2012 and is based in Hemel Hempstead, the United Kingdom. MEDIVIE THERP is traded on Tel Aviv Stock Exchange in Israel.
Please note, the presentation of Medivie Therapeutic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Medivie Therapeutic's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Medivie Therapeutic's management manipulating its earnings.
Medivie Therapeutic Workforce Analysis
Traditionally, organizations such as Medivie Therapeutic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medivie Therapeutic within its industry.Medivie Therapeutic Manpower Efficiency
Return on Medivie Therapeutic Manpower
Revenue Per Employee | 44.6K | |
Revenue Per Executive | 49.1K | |
Net Loss Per Employee | 599.5K | |
Net Loss Per Executive | 659.4K |
Complementary Tools for Medivie Stock analysis
When running Medivie Therapeutic's price analysis, check to measure Medivie Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medivie Therapeutic is operating at the current time. Most of Medivie Therapeutic's value examination focuses on studying past and present price action to predict the probability of Medivie Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medivie Therapeutic's price. Additionally, you may evaluate how the addition of Medivie Therapeutic to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |